{"entity":{"id":"pde3b","kind":"target","name":"PDE3B","aka":["phosphodiesterase 3B","cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B","HcGIP1"],"tldr":"PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.","summary":"Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signalling. Controls cardiac contractility by reducing cAMP concentration in cardiocytes.\n\nOpen Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.75, animal model 0.36, genetic association 0.16, clinical 0.96).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:8779","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8779"},{"label":"UniProt Q13370","url":"https://www.uniprot.org/uniprotkb/Q13370/entry"},{"label":"NCBI Gene 5140","url":"https://www.ncbi.nlm.nih.gov/gene/5140"},{"label":"Ensembl ENSG00000152270","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152270"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["myeloproliferative-neoplasms","essential-thrombocythaemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PDE3B","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:8779","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8779","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q13370","url":"https://www.uniprot.org/uniprotkb/Q13370/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000152270","url":"https://platform.opentargets.org/target/ENSG00000152270/associations","note":"association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.58, essential thrombocythemia 0.58 (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PDE3B: RNA tissue enhanced (adipose tissue 61 nTPM); blood lineage group enriched (granulocytes 4 nTPM, T-cells 6 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (essential thrombocythemia). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas PDE3B tissue","url":"https://www.proteinatlas.org/ENSG00000152270-PDE3B/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000152270 associations","url":"https://platform.opentargets.org/target/ENSG00000152270/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:8779","ensembl":"ENSG00000152270","uniprot":"Q13370","entrez":"5140","firstDescribed":1996,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Miki et al, Genomics, 1996, \"Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8884271/","biology":"Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signalling. Controls cardiac contractility by reducing cAMP concentration in cardiocytes. Location: Membrane (UniProt). Locus 11p15.2 (HGNC).","whereFound":["Myeloproliferative neoplasms: Open Targets association 0.58 with myeloproliferative neoplasm (MONDO_0020076)","Essential thrombocythaemia: Open Targets association 0.58 with essential thrombocythemia (MONDO_0005029)"],"targetClass":"enzyme","prevalence":[]},"route":"/targets/pde3b/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}]}}